David Shechter, Ph.D.
Albert Einstein College of Medicine, Inc.
Funded by LUNG FORCE
When the Writing Goes Wrong: Protein Arginine Methyltransferases in Lung Cancer
Protein modification by methylation, the addition of a small chemical flag that regulates that protein's function, is frequently disrupted in lung cancer. Our proposal aims to understand why a class of enzymes that adds a methyl group to protein building blocks called arginine is disrupted in lung cancer cells and importantly how drugging these enzymes could be a novel chemotherapy. We will test, in lung cancer cells, specific drugs against these enzymes, one of which is currently in phase I trials, in combination with a range of other drugs to understand how they could work in combination. We will also probe specific and important molecular events that are regulated by these enzymes, in lung cancer cells. The information we develop from this study will potentially lead to improved chemotherapeutic approaches in lung and other human cancers.
Sign up for the latest lung health news delivered right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.